Department of Pharm. Technology, Institute of Pharmacy, University of Bonn, Germany.
Int J Pharm. 2012 Oct 15;436(1-2):299-310. doi: 10.1016/j.ijpharm.2012.06.025. Epub 2012 Jun 19.
As primary brain tumors, malignant gliomas are known to be one of the most insidious types of brain cancer afflicting the humans. The current standard strategy for the treatment of malignant gliomas includes the surgical resection of the tumor when possible, followed by a combination of radiotherapy and/or a certain chemotherapeutic protocol. However, due to the short mean survival, frequent recurrences, and poor prognosis associated with the tumors, new therapeutic strategies are investigated consecutively. These novel drug delivery approaches can be subdivided as systemic and local drug administration. This review focuses on localized drug delivery strategies for the treatment of malignant gliomas, including the injections, infusions, trans-nasal delivery systems, convection enhanced delivery (CED) systems, and various types of polymeric implants. Furthermore, systemic strategies to increase the drug penetration into the brain, such as temporary disruption of the blood brain barrier (BBB), chemical modification of the available therapeutic substances, and utilization of endogenous transport systems will be briefly discussed.
作为原发性脑肿瘤，恶性神经胶质瘤是已知的最阴险的脑癌类型之一，影响人类。目前治疗恶性神经胶质瘤的标准策略包括在可能的情况下进行肿瘤切除，然后结合放疗和/或特定的化疗方案。然而，由于肿瘤相关的平均存活时间短、频繁复发和预后不良，新的治疗策略正在被连续研究。这些新的药物输送方法可以分为系统和局部药物给药。本综述重点介绍了用于治疗恶性神经胶质瘤的局部药物输送策略，包括注射、输注、经鼻给药系统、对流增强输送（CED）系统和各种类型的聚合物植入物。此外，还将简要讨论增加药物穿透大脑的系统策略，如暂时破坏血脑屏障（BBB）、对现有治疗物质进行化学修饰以及利用内源性转运系统。
